Agilent Technologies Inc vs Matson Inc — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Matson Inc trades at $204.7 (market cap $6.24B). The key difference: Agilent Technologies Inc is far larger — about 6.7× Matson Inc's market cap, and Matson Inc pays the higher dividend (0.73%). Which is the better fit depends on your goals.
| A | MATX | |
|---|---|---|
Market Cap | $42.00B | $6.24B |
Sector | Health | Technology |
52-Week High | $157.20 | $223.55 |
52-Week Low | $110.24 | $88.05 |
Enterprise Value | $43.55B | $6.84B |
Dividend Yield | 0.69% | 0.73% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Matson (MATX) trades at $206.77, up 0.25% today, with strong technical momentum showing bullish moving averages and support at $205. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $4.27 versus $3.79 expected, and has raised full-year guidance. Valuation remains attractive with a P/E of 14.08 and EV/EBITDA of 7.93, while profitability metrics show a net income margin of 13.41% and ROE of 17.21%.
Outlook remains positive with analyst consensus pointing to 27% upside to $265 price target, supported by continued momentum in China services and resilient consumer demand. Key risks include exposure to Trans-Pacific trade volatility and competitive pressures in shipping markets. The combination of earnings momentum, reasonable valuation, and institutional support suggests favorable risk-reward for investors.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →